The progression-free survival and overall survival of NSCLC patients with EGFR-active gene mutations are significantly improved after treatment with gefitinib, and as a result, the FDA approved gefitinib as a first-line therapy for NSCLC in 2015 [7, 8]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.